Stock Research for TGTX

TGTX

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

TGTX Stock Chart & Research Data

The TGTX chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the TGTX chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


TGTX Due diligence Resources & Stock Charts

The TGTX stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View TGTX Detailed Price Forecast - CNN Money CNN View TGTX Detailed Summary - Google Finance
Yahoo View TGTX Detailed Summary - Yahoo! Finance Zacks View TGTX Stock Research & Analysis - Zacks.com


Stock Analysis

TradeIdeas View TGTX Trends & Analysis - Trade-Ideas Barrons View TGTX Major Holders - Barrons
NASDAQ View TGTX Call Transcripts - NASDAQ Seeking View TGTX Breaking News & Analysis - Seeking Alpha
Spotlight View TGTX Annual Report - CompanySpotlight.com OTC Report View TGTX OTC Short Report - OTCShortReport.com
TradeKing View TGTX Fundamentals - TradeKing Charts View TGTX SEC Filings - Bar Chart
WSJ View Historical Prices for TGTX - The WSJ Morningstar View Performance/Total Return for TGTX - Morningstar
MarketWatch View the Analyst Estimates for TGTX - MarketWatch CNBC View the Earnings History for TGTX - CNBC
StockMarketWatch View the TGTX Earnings - StockMarketWatch MacroAxis View TGTX Buy or Sell Recommendations - MacroAxis
Bullish View the TGTX Bullish Patterns - American Bulls Short Pains View TGTX Short Pain Metrics - ShortPainBot.com


Social Media Mentions

StockTwits View TGTX Stock Mentions - StockTwits PennyStocks View TGTX Stock Mentions - PennyStockTweets
Twitter View TGTX Stock Mentions - Twitter Invest Hub View TGTX Investment Forum News - Investor Hub
Yahoo View TGTX Stock Mentions - Yahoo! Message Board Seeking Alpha View TGTX Stock Mentions - Seeking Alpha






Financial & Transaction Holdings

SECform4 View Insider Transactions for TGTX - SECform4.com Insider Cow View Insider Transactions for TGTX - Insider Cow
CNBC View TGTX Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for TGTX - OTC Markets
Yahoo View Insider Transactions for TGTX - Yahoo! Finance NASDAQ View Institutional Holdings for TGTX - NASDAQ


Stock Charts

FinViz View TGTX Stock Insight & Charts - FinViz.com StockCharts View TGTX Investment Charts - StockCharts.com
BarChart View TGTX Stock Overview & Charts - BarChart Trading View View TGTX User Generated Charts - Trading View


Latest Financial News for TGTX

TG Therapeutics and Novimmune SA Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
Posted on Wednesday June 20, 2018

TG Therapeutics, Inc. (TGTX) and Novimmune SA, today announced that the companies have entered into an exclusive global agreement to collaborate on the development and commercialization of Novimmune’s novel first-in-class anti-CD47/anti-CD19 bispecific antibody known as TG-1801 (previously NI-1701). TG Therapeutics will make up-front and milestones payments based on early clinical development, and will be responsible for the costs of clinical development of the products through the end of Phase II, after which TG Therapeutics and Novimmune will be jointly responsible for all development and commercialization costs of the product.


TG Therapeutics, Inc. Announces Updated Results from the Ongoing Phase 2 Study of Ublituximab in Patients with Multiple Sclerosis at the 4th Congress of the European Academy of Neurology
Posted on Monday June 18, 2018

TG Therapeutics, Inc. (TGTX), today announced updated results from the Phase 2 multicenter trial of ublituximab (TG-1101), the Company’s novel glycoengineered anti-CD20 monoclonal antibody, in relapsing forms of Multiple Sclerosis (RMS). The data is being presented today at the 4th Congress of the European Academy of Neurology in Lisbon, Portugal, via an oral session titled “MS and related Disorders 2”, at 17:00 CET. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to see that the preliminary Week 48 data presented today from this Phase 2 trial supports the Week 24 data presented earlier this year at the AAN meeting.


TG Therapeutics, Inc. Presents Phase 2 Data Evaluating Umbralisib in CLL Patients Intolerant to Prior BTK or PI3K Delta Inhibitor Therapy at the 23rd Congress of the European Hematology Association (EHA)
Posted on Monday June 18, 2018

TG Therapeutics, Inc. (TGTX), today announced an oral presentation of clinical data from its ongoing Phase 2 study evaluating umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL) who are intolerant to prior BTK or PI3K delta inhibitor therapy. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are pleased to present data evaluating umbralisib in patients intolerant to currently approved BTK or PI3K therapies during the EHA annual congress.


TG Therapeutics, Inc. Announces Clinical and Preclinical Data Presentations at the 23rd Congress of the European Hematology Association
Posted on Friday June 15, 2018

TG Therapeutics, Inc. (TGTX), today announced the presentation of an integrated analysis of long term safety data of umbralisib (TGR-1202), the Company’s PI3K delta inhibitor, either dosed as a single agent and in combination, in patients with relapsed or refractory lymphoid malignancies, as well as the first preclinical data presentation of TG-1701, the Company’s orally available and covalently-bound BTK inhibitor. Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, stated, “We are extremely pleased to present updated data from our integrated safety analyses of umbralisib.


Enter a stock symbol to view the stock details.